FIGURE 5. CD70 but not CD80/CD86 signaling in Batf3 dependent cells plays a critical role in expansion and antitumor efficacy of infused Pmel-1 T cells.

(A) Frequency of infused Pmel-1 T cells (CD8⁺ CD90.1⁺) among total CD45⁺ cells in peripheral blood of B16 tumor-bearing mixed bone marrow chimera mice (Batf3^−/− and WT→WT, Batf3^−/− and CD70^−/−→WT mice, or Batf3^−/− and CD80^−/−→WT mice) 7 days after ACT ± Vac (hgp100, agonistic anti-CD40 Ab, and TLR7 agonist). (n = 5–7 mice per group). NS, not significant, *P <0.05, ***P <0.001 by one-way ANOVA with Tukey’s multiple comparisons. Mice were irradiated (500 cGy) before ACT.

(B) Survival curves in B16 tumor-bearing mixed bone marrow chimera mice (Batf3^−/− and WT→WT, Batf3^−/− and CD70^−/−→WT mice, Batf3^−/− and CD80^−/−→WT mice) treated with ACT ± Vac (hgp100, agonistic anti-CD40 Ab, and TLR7 agonist) (n = 6–13 mice per group). Data shown are pooled from two independent experiments. *P < 0.05, ***P < 0.001 using log-rank (Mantel-Cox) test.

Values are mean ± SEM.